Outlook Therapeutics (OTLK) Finished Goods (2025 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Finished Goods of $201903.0 for Q1 2026, down 93.94% year-over-year from $3.3 million in Q1 2025, and up 581.51% quarter-over-quarter from $29626.0 in Q3 2025.
Outlook Therapeutics (OTLK) Finished Goods (2025 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Finished Goods for 2 consecutive years, with $201903.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Finished Goods fell 93.94% year-over-year to $201903.0; the TTM figure through Mar 2026 stood at $201903.0 (down 93.94% YoY), while the FY2025 annual figure was $29626.0, changed N/A from the prior year.
- Finished Goods climbed to $201903.0 in Q1 2026 per OTLK's latest filing, from $29626.0 in the prior quarter.
- Across five years, Finished Goods topped out at $3.3 million in Q1 2025 and bottomed at $29626.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,903.00 |
| Sep 30, 2025 | 29,626.00 |
| Jun 30, 2025 | 377,223.00 |
| Mar 31, 2025 | 3.33 Mn |